Breaking News
Get 40% Off 0
🚨 Volatile Markets? Find Hidden Gems for Serious Outperformance
Find Stocks Now
Close

Citius Pharmaceuticals Inc (CTXR)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Follow Citius Pharma's earnings

Delivery Method

Status

Add to/Remove from a Portfolio Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
0.717 +0.010    +1.40%
16:08:13 - Real-time Cboe. Currency in USD ( Disclaimer )
  • Volume: 240,559
  • Bid/Ask: 0.000 / 0.000
  • Day's Range: 0.700 - 0.730
Type:  Equity
Market:  United States
Citius Pharma 0.717 +0.010 +1.40%

Citius Pharma Company Profile

 
Read the Citius Pharmaceuticals Inc company profile to learn more about the business and the management team. View Citius Pharmaceuticals Inc facts about employee data, company products and services, and contact information.
IndustryBiotechnology & Medical Research
SectorHealthcare
Employees

22

Equity Type

ORD

Citius Pharmaceuticals, Inc., a late-stage pharmaceutical company, engages in the development and commercialization of critical care products focusing on oncology products, anti-infectives products in adjunct cancer care, prescription products, and stem cell therapy. It is developing five proprietary products comprising LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma, which is in Phase 3 clinical trial; Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections by salvaging the infected catheter, which is in Phase 3 clinical trial; Halo-Lido, a corticosteroid-lidocaine topical formulation that intends to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids that is in clinical Phase 2b trial; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; and NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome. The company was founded in 2007 and is headquartered in Cranford, New Jersey.

Contact Information

Address 11 Commerce Drive First Floor
Cranford, 07016
United States
Phone 908 967 6677
Fax -

Top Executives

Name Age Since Title
Suren G. Dutia 81 2015 Independent Director
Leonard L. Mazur 79 2014 Co-Founder, CEO, Chairman & Secretary
Carol A. Webb 77 2016 Independent Director
Myron Z. Holubiak 77 2015 Co-Founder & Executive Vice Chairman
Mark Rupp - - Member of Scientific Advisory Board
Leonard A. Mermel - 2018 Member of Scientific Advisory Board
Issam Raad - - Chairman of Scientific Advisory Board
Perenlei Enkhbaatar - - ARDS Scientific Advisory Board Member
Eugene Holuka 65 2016 Independent Director
John G. Laffey - 2021 ARDS Scientific Advisory Board Member
Mitchell M. Levy - - ARDS Scientific Advisory Board Member
Dennis M. McGrath 67 2023 Independent Director
Lorraine B. Ware - - ARDS Scientific Advisory Board Member
Michael A. Matthay - - ARDS Scientific Advisory Board Member
Joel Rosenblatt - - Member of Scientific Advisory Board
Robert J. Smith 63 2024 Independent Director
Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

CTXR Price Commentary

Write your thoughts about Citius Pharmaceuticals Inc
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
GÖKHAN BALCI
GÖKHAN BALCI Jul 20, 2023 16:42
Saved. See Saved Items.
This comment has already been saved in your Saved Items
will fly very soon
Alun Benjamin
Alun Benjamin May 04, 2023 13:58
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Cap-xx did the exact same thing to me this morning. Share price plummeted from £2.60 to £1.30, where it will no doubt meet its demise. who would have imagined Citius would stitch me up again, in an identical fashion, barely 10 hours later?
Alun Benjamin
Alun Benjamin May 04, 2023 13:54
Saved. See Saved Items.
This comment has already been saved in your Saved Items
cnts
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email